Publikationen in Zusammenarbeit mit Forschern von Centro de Investigación Biomédica en Red de Cáncer (8)

2024

  1. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  2. Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer (Molecular Cancer, (2023), 22, 1, (86), 10.1186/s12943-023-01788-w)

    Molecular Cancer

  3. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

  4. The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer

    Molecular Cancer, Vol. 22, Núm. 1

2020

  1. Id1 and pd-1 combined blockade impairs tumor growth and survival of KRAS-mutant lung cancer by stimulating PD-l1 expression and tumor infiltrating CD8+ T cells

    Cancers, Vol. 12, Núm. 11, pp. 1-22

2019

  1. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

2018

  1. KRAS oncogene in non-small cell lung cancer: Clinical perspectives on the treatment of an old target

    Molecular Cancer, Vol. 17, Núm. 1